オーストラリアでは、高率の副作用のため、5歳以下の季節風邪インフルエンザ予防注射を停止

オーストラリアでは、高率の副作用のため、5歳以下の季節風邪インフルエンザ予防注射を停止

オーストラリアでは、5歳以下のCSL製薬会社のFLUVAX季節風邪インフルエンザ予防接種の高い率の高熱や発作的な発熱の副作用の症状が起こっているので、健康な5歳以下のすべての季節風邪インフルエンザの予防接種を停止するよう勧告している。既成症状もちの子供で、もし風邪にかかったら、重症化する危険のある恐れのある5歳以下の患者は、予防接種の副作用の弊害と、よく考えて、秤(はかり)にかけて、医者と相談するように。もし、5歳以下の子供に季節風邪いんふるえんざの予防接種をする場合には、医者とよく相談して、VAXIGRIP か、INFLUVAC を接種するように。2010年07月30日

Departmental Media Releases

Seasonal flu vaccination for young children can be resumed - Updated advice from the Chief Medical Officer
Continued close monitoring of side effects with this year's seasonal flu vaccine in children under five years of age has shown that the higher than usual occurrence of fever and febrile convulsions appears to be confined to the vaccine Fluvax, manufactured by CSL so parents can now seek advice from their doctor to use other brands on the market if they want their young children vaccinated.

In this section:
Departmental Media Releases
Seasonal Flu Vaccine and young children
Australia and New Zealand Food Regulation Ministerial Council Final Communiqué
Australian Health Ministers’ Conference Communique
CMO To Step Down
Design of New National Registration and Accreditation Scheme
Dr Mukesh Haikerwal
Food Ministers Agree To A Strategic Vision For Australian And New Zealand Food Regulation System
Food Ministers Consider Food Labelling Review
Government on Track to Close the Gap on Infant Mortality
GPs are major players in H1N1 Influenza 09
Health authorities continue to put seasonal flu vaccine on hold for young children
Indigenous Australians recognised in H1N1 Influenza 09 Health Response
Joint Communiqué - Gene Technology Ministerial Council
National Medical Director of Organ and Tissue Donation and Transplantation Authority Appointed
New Commonwealth Chief Nurse Appointed
On Target to Halve the Gap in Indigenous Child Mortality
PBS listing to help prevent invasive fungal infections
Preventative Health Taskforce - Media Release
Prominent cancer specialist appointed new Commonwealth Chief Medical Officer
Prudent measures to conserve anti-coagulant medicines
Seasonal flu vaccination for young children can be resumed - Updated advice from the Chief Medical Officer
Seasonal Flu Vaccine Remains Suspended for young children without risk factors - Advice from the Chief Medical Officer
Self-Test Bowel Cancer Kits – Important Notice for Users
Serious adverse events identified in Queensland with the use of Peripherally Inserted Central Catheters (PICC lines)
Talk, tell, transform lives - Australians urged to make a new kind of New Year’s resolution in 2009
view more in this section
view less in this sectionPDF printable version of Seasonal flu vaccination for young children can be resumed - Updated advice from the Chief Medical Officer (PDF 57 KB)

30 July 2010

Continued close monitoring of side effects with this year's seasonal flu vaccine in children under five years of age has shown that the higher than usual occurrence of fever and febrile convulsions appears to be confined to the vaccine Fluvax, manufactured by CSL.

In my last report to parents and the medical profession on June 1 this year, I highlighted that Fluvax appeared to be the main concern but that, because of limited use there was insufficient evidence about the extent of fever and febrile convulsions associated with the other vaccines on the market.

I therefore continued to recommend the suspension of use of all seasonal flu vaccinations for healthy children under 5 years of age. At the same time I also encouraged parents to speak with their doctor about vaccination if a child had an underlying medical condition where flu could be harmful to the child and to carefully weigh the risks and benefits of vaccination in each individual child.

Since that announcement continued investigations in Australia and overseas indicate that there does not appear to be the higher than normal incidence of febrile convulsions in children under five with the other seasonal flu vaccines Influvac and Vaxigrip.

In particular, data from Australia and New Zealand show that rates of fever and febrile convulsions associated with Vaxigrip and Influvac are similar to those seen with trivalent seasonal flu vaccine in previous years.

While to date it has still not been possible to identify a biological or other basis that would explain the higher than expected observed rates of fever and febrile convulsions with Fluvax, the investigations are continuing.

In the meantime I am now advising that if parents of children under five years of age wish to have their children vaccinated against seasonal flu that they should discuss with their GP or vaccine provider the use of Vaxigrip or Influvac.

It should be noted that influenza itself often causes fever in young children which can lead to febrile convulsions and that all flu vaccines can cause this side effect which, if handled properly, is usually short lived. I am writing to all GPs and immunisation providers to advise them of my latest advice and to ask doctors to explain to parents what to do if fever occurs following vaccination.

More information is available on the Immunise Australia Hotline at 1800 671 811.

Media contact: Kay McNiece, 0412 132 585